Long term persistance of yellow fever neutralising antibodies in elderly persons;Persistance à long terme des anticorps neutralisants de la fièvre jaune chez les personnes âgées de 60 ans et plus

Bulletin de la Societe de Pathologie Exotique

Volumn 104, Issue 4, 2011, Pages 260-265

  Coulange Bodilis, H ^a   Benabdelmoumen, G ^a   Gergely, A ^a   Goujon, C ^a   Pelicot, M ^a   Poujol, P ^a   Consigny, P H ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

Elderly people; Long term protection; Neutralising antibodies; Travellers; Yellow fever vaccine

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; YELLOW FEVER VACCINE;

AGED; ARTICLE; BLOOD; DRUG CONTRAINDICATION; HUMAN; IMMUNOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; TIME; TRAVEL; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS;

AGED; AGED, 80 AND OVER; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TRAVEL; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

EID: 80054955587     PISSN: 00379085     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13149-011-0135-7     Document Type: Article

References (14)

1. Amanna IJ, Messaoudi I, Slifka MK (2008) Protective immunity following vaccination: how is it defined? Hum Vaccin 4(4): 316-9. Epub 2008 Feb 19.
2. Barnett ED, Wilder-Smith A, Wilson ME (2008) Yellow fever vaccines and international travelers. Expert Rev Vaccines 7(5):579-87. (Pubitemid 351881342)
3. es Journées nationales d'infectiologie, Lyon.
4. Hepburn MJ, Kortepeter MG, Pittman PR, et al (2006) Neutralizing antibody response to booster vaccination with 17D yellow fever vaccine. Vaccine 24(15):2843-9. Epub 2006 Jan 18.
5. Khromava AY, Eidex RB, Weld LH et al (2005) Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 23(25):3256-63. (Pubitemid 40523118)
6. Monath TP, Cetron MS (2002) Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis 34(10):1369-78. Epub 2002 Apr 2. (Pubitemid 34507947)
7. Monath TP, Nichols R, Archambault WT et al (2002) Comparative safety and immunogenicity of two yellow fever 17D vaccines (Arilvax" and YF-VAX) in a phase III multicenter, doubleblind clinical trial. Am J Trop Med Hyg 66(5):533-41.
8. Niedrig M, Lademann M, Emmerich P, Lafrenz M (1999) Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and Elisa. Trop Med Int Health 4(12):867-71. (Pubitemid 30041042)
9. Poland JD, Calisher CH, Monath TP et al (1981) Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 59(6):895-900. (Pubitemid 12155776)
10. Roukens AH, Vossen AC, Bredenbeek PJ, et al (2008) Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled noninferiority trial. PloS One 3(4):e1993.
11. Roukens AH, Vossen AC, van Dissel JT, Visser LG (2009) Reduced intradermal test dose of yellow fever vaccine induces protective immunity in individuals with egg allergy. Vaccine 27(18): 2408-9. Epub 2009 Feb 24.
12. es Actualités du Pharo, Marseille.
13. es Journées nationales d'infectiologie, Bordeaux.
14. Veit O, Niedrig M, Chapuis-Taillard C, et al (2009) Immunogenicity and safety of yellow fever vaccination for 102-HIV infected patients. Clin Infect Dis 48(5):659-66.